Uppsala-based Ilya Pharma has been awarded EUR 2.99 million (about SEK 30 million) from the European Commission in the face of tough international competition. The company, which develops next-generation biological drugs for treating wounds in skin and mucous membranes, has thus secured funding to obtain the first clinical data for its new drug candidate.
Every year the Nobel Assembly at Karolinska Institute announces the Laureates of the Nobel Prize in Physiology or Medicine following a traditional ceremony. Professor Mia Phillipson, one of the cofounders of Ilya Pharma was specially invited to the studio (DI-tv) to give her view and comment the topic and the work of the three Laureates. The Nobel Prize was awarded Jeffery C. Hall, Michael Rosebush and Michael W. Young for their discoveries in genetics and concomitant functions relating to the circadian rhythm. Professor Mia Phillipson is leading the field of immunophysiology and have also published in the field of circadian rhythm and functions of a specific type of immune cells, affected by one night of sleep deprivation.
PharmabioticsGlobal 2017 is organized by the Pharmabiotics Research Institute in Paris 15th to the 17th of March. ILYA Pharma will do a presentation at the Startup Showcase session together with other companies using the microbiome to develop new innovative treatments.
In competition with more than 650 other companies ILYA Pharma receives a grant of €30.000 from VINNOVA Innovative Startups program. Evelina Vågesjö, CEO ILYA Pharma, comments happily:
ILYA Pharma was specifically invited by nomination to present our case to an audience of Investors in Life Science and representatives from large Pharma companies.
As one of 10 outstanding start-up companies presenting an innovative product currently in pipeline ILYA Pharma won the ATTD Startup grant at the prestigious International Fair of New Technologies during ATTD, 2017, that was held in Paris, 15-18th of February.